Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition

Hepatology

Volumn 43, Issue 5, 2006, Pages 973-981

  Callender, Glenda G ^a   Rosen, Hugo R ^b   Roszkowski, Jeffrey J ^a   Lyons, Gretchen E ^a   Li, Mingli ^a   Moore, Tamson ^a   Brasic, Natasha ^a   McKee, Mark D ^a   Nishimura, Michael I ^a,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HLA A2 ANTIGEN; NONSTRUCTURAL PROTEIN 3; T LYMPHOCYTE RECEPTOR; TETRAMER;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CLONING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL; VIRUS IDENTIFICATION;

ANTIGENS, CD8; CELLS, CULTURED; HEPACIVIRUS; HUMANS; RECEPTORS, ANTIGEN, T-CELL;

EID: 33646596604     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21157     Document Type: Article

References (34)

1. National Centers for Disease Control and Prevention. Hepatitis C fact sheet. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact/html. Accessed November 2005.
2. Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003;9(Suppl):S35-S43.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
5. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003;7:149-161.
6. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-1719.
7. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000;20:127-141.
8. Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 2000;242:299-325.
9. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
10. Takaki A, Wiese M, Maerten G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist, humoral response responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nat Med 2000;6:578-582.
11. Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004;114:250-259.
12. Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci 2003;28:287-304.
13. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery following acute hepatitis c virus infection from a shared source. J Exp Med 2005;201:1725-1731.
14. Hunziker IP, Zurbriggen R, Glueck R, Engler OB, Reichen J, Dai WJ, et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 2001;38:475-484.
15. + T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004;173:5355-5359.
16. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999;20:1820-1822.
17. Kaplan BLF, Yu DC, Clay TM, Nishimura MI. Redirecting T lymphocyte specificity using T cell receptor genes. Int Rev Immunol 2003;22:229-253.
18. Roszkowski JJ, Yu DC, McKee MD, Cole DJ, McKee, MD, Nishimura MI. CD8 independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol 2003;170:2582-2589.
19. + melanoma reactive T cells by retroviral mediated transfer of a single TCR. Cancer Res 2005;65:1570-1576.
20. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005;22:117-129.
21. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.J Immunol 1989;142:3714-3725.
22. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-3157.
23. Anglard P, Trahan E, Liu S, Latif F, Merino MJ, Lerman MI, et al. Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res 1992;52:348-356.
24. Langerman A, Callender GG, Nishimura MI. Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bi-functional) t cells reactive with two defined antigens. J Transl Med 2004;2:42.
25. Nishimura MI, Kawakami Y, Charmley P, O'Neil B, Shilyansky J, Yannelli JR, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother 1994;16:85-94.
26. Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci U S A 1994;91:2829-2833.
27. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163:507-513.
28. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995;55:748-752.
29. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996;93:4102-4107.
30. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
31. Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999;22:288-298.
32. Irwin MJ, Heath WR, Sherman LA. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 1989;170:1091-1101.
33. Newberg MH, Ridge JP, Vining DR, Salter RD, Engelhard VH. Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules. J Immunol 1992;149:136-142.
34. + T cells in chronic hepatitis C virus infection. J Immunol 2002;169:3447-3458.